Home
CYTK
CYTK News

Latest Cytokinetics Incorporated (CYTK) News on October 25, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

8 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed?

Simply Wall St.

23 days ago

Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed?

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?

Zacks

23 days ago

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?

MT Newswires

24 days ago

Cytokinetics Insider Sold Shares Worth $275,250, According to a Recent SEC Filing

MT Newswires

25 days ago

Cytokinetics Insider Sold Shares Worth $368,761, According to a Recent SEC Filing

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential?

Simply Wall St.

a month ago

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential?

Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress

Insider Monkey

4 months ago

Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress

Argus Research

4 months ago

CYTK: Rating decreased to a SELL

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan

Insider Monkey

4 months ago

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan

Argus Research

4 months ago

CYTK: Raising target price to $36.00

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

GlobeNewswire

4 months ago

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Zacks

5 months ago

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

MT Newswires

5 months ago

Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating

Argus Research

5 months ago

CYTK: Rating increased to a HOLD

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

GlobeNewswire

5 months ago

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Simply Wall St.

5 months ago

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

GlobeNewswire

5 months ago

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Argus Research

5 months ago

CYTK: Lowering target price to $24.00

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

GlobeNewswire

5 months ago

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

GlobeNewswire

6 months ago

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

MT Newswires

6 months ago

B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

6 months ago

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Cytokinetics to Hold Annual Meeting of Stockholders

GlobeNewswire

6 months ago

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

Zacks

6 months ago

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

MT Newswires

6 months ago

RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk

Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges

GuruFocus.com

6 months ago

Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges

Argus Research

6 months ago

CYTK: Lowering target price to $27.00

MT Newswires

6 months ago

Cytokinetics Q1 Net Loss Widens, Revenue Rises

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Zacks

6 months ago

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

6 months ago

Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings

Why Cytokinetics, Inc. (CYTK) Went Down On Friday

Insider Monkey

6 months ago

Why Cytokinetics, Inc. (CYTK) Went Down On Friday

MT Newswires

6 months ago

Sector Update: Health Care Stocks Climb Late Afternoon

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

Benzinga

6 months ago

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

MT Newswires

6 months ago

Cytokinetics Shares Fall After FDA Extends Review of Heart Disease Treatment

MT Newswires

6 months ago

UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

BioPharma Dive

6 months ago

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire

6 months ago

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Participate in May Investor Conferences

GlobeNewswire

6 months ago

Cytokinetics to Participate in May Investor Conferences

Argus Research

6 months ago

CYTK: Lowering target price to $30.00

Cytokinetics to Announce First Quarter Results on May 6, 2025

GlobeNewswire

6 months ago

Cytokinetics to Announce First Quarter Results on May 6, 2025

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

TipRanks

6 months ago

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

MT Newswires

6 months ago

Cytokinetics Insider Sold Shares Worth $769,200, According to a Recent SEC Filing

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?

Insider Monkey

6 months ago

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

6 months ago

CYTK: Raising target price to $31.00

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

Zacks

6 months ago

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

Bristol Myers stumbles in bid to widen heart drug’s use

BioPharma Dive

6 months ago

Bristol Myers stumbles in bid to widen heart drug’s use

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Investor's Business Daily

6 months ago

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

The Wall Street Journal

6 months ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Argus Research

7 months ago

CYTK: Lowering target price to $28.00

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Zacks

7 months ago

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Investor's Business Daily

7 months ago

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Investopedia

7 months ago

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Argus Research

7 months ago

CYTK: Lowering target price to $30.00

MT Newswires

7 months ago

Cytokinetics Insider Sold Shares Worth $611,250, According to a Recent SEC Filing

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

7 months ago

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy

Insider Monkey

7 months ago

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy

Argus Research

7 months ago

CYTK: Raising target price to $36.00

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey

7 months ago

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Zacks

7 months ago

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

GlobeNewswire

7 months ago

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Cytokinetics Insider Sold Shares Worth $943,426, According to a Recent SEC Filing

MT Newswires

7 months ago

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

GlobeNewswire

7 months ago

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

MT Newswires

8 months ago

Cytokinetics Insider Sold Shares Worth $1,080,750, According to a Recent SEC Filing

MT Newswires

8 months ago

Cytokinetics Insider Sold Shares Worth $374,900, According to a Recent SEC Filing

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Simply Wall St.

8 months ago

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Argus Research

8 months ago

CYTK: Lowering target price to $35.00

Cytokinetics to Participate in March Investor Conferences

GlobeNewswire

8 months ago

Cytokinetics to Participate in March Investor Conferences

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

8 months ago

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Zacks

8 months ago

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Cytokinetics Inc Earnings Call

MT Newswires

8 months ago

Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

GuruFocus.com

8 months ago

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Zacks

8 months ago

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Associated Press Finance

8 months ago

Cytokinetics: Q4 Earnings Snapshot

MT Newswires

8 months ago

Cytokinetics Q4 Net Loss Narrows, Revenue Rises

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

Cytokinetics Inc (CYTK) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

8 months ago

Cytokinetics Inc (CYTK) Q4 2024: Everything You Need To Know Ahead Of Earnings

Argus Research

8 months ago

CYTK: Raising target price to $37.00

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey

8 months ago

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Insider Monkey

8 months ago

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

8 months ago

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

8 months ago

CYTK: Raising target price to $36.00

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

GlobeNewswire

8 months ago

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

MT Newswires

8 months ago

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Adjusts Price Target to $67 From $70

MT Newswires

8 months ago

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70

Cytokinetics Names Robert E. Landry to Board of Directors

GlobeNewswire

8 months ago

Cytokinetics Names Robert E. Landry to Board of Directors

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey

9 months ago

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

MT Newswires

9 months ago

Citigroup Initiates Cytokinetics at Buy With $86 Price Target

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

9 months ago

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MT Newswires

9 months ago

B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating

Argus Research

9 months ago

CYTK: What does Argus have to say about CYTK?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Share on Social Networks: